Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis.
暂无分享,去创建一个
P. Rabinovitch | R. Haggitt | T. Brentnall | C. Rubin | D. Crispin | A. Stevens | G. Burmer | G. C. Burmer | David A. Crispin
[1] N. Harpaz,et al. p53 point mutations in dysplastic and cancerous ulcerative colitis lesions. , 1993, Gastroenterology.
[2] L. Castagnetta,et al. Estrogen receptor variant messenger RNA lacking exon 4 in estrogen-responsive human breast cancer cell lines. , 1993, Cancer research.
[3] Leland Hartwell,et al. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells , 1992, Cell.
[4] M. Kimmey,et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. , 1992, Gastroenterology.
[5] P. Rabinovitch,et al. Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele. , 1992, Gastroenterology.
[6] R. Metcalf,et al. p53 mutation and protein accumulation during multistage human esophageal carcinogenesis. , 1992, Cancer research.
[7] U. Pastorino,et al. Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. , 1992, Cancer research.
[8] D. Lane,et al. p53, guardian of the genome , 1992, Nature.
[9] K. Kinzler,et al. Oncogenic forms of p53 inhibit p53-regulated gene expression , 1992 .
[10] B. Vogelstein,et al. The relationship of DNA aneuploidy to molecular genetic alterations in colorectal carcinoma. , 1992, Gastroenterology.
[11] B. Vogelstein,et al. Clonal origin of bladder cancer. , 1992, The New England journal of medicine.
[12] R. Metcalf,et al. Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners , 1992, The Lancet.
[13] D. Neal,et al. c-erbB-2 amplification and identical p53 mutations in concomitant transitional carcinomas of renal pelvis and urinary bladder , 1992, The Lancet.
[14] B. Vogelstein,et al. Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.
[15] Patricia L. Blount,et al. Distribution of aneuploid cell populations in ulcerative colitis with dysplasia or cancer. , 1991, Gastroenterology.
[16] P. Rabinovitch,et al. Frequent loss of a p53 allele in carcinomas and their precursors in ulcerative colitis. , 1991, Cancer communications.
[17] J. Milner,et al. Tumor suppressor p53: analysis of wild-type and mutant p53 complexes , 1991, Molecular and cellular biology.
[18] B. Vogelstein,et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. , 1990, Cancer research.
[19] R. Riddell. Dysplasia in Ulcerative Colitis , 1990 .
[20] M. Leppert,et al. Allelic Loss in Colorectal Carcinoma , 1989 .
[21] G. Salzman. New Technologies in Cytometry , 1989 .
[22] D. Ledbetter,et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. , 1989, Science.
[23] I. Herskowitz. Functional inactivation of genes by dominant negative mutations , 1987, Nature.
[24] P. Nowell. Mechanisms of tumor progression. , 1986, Cancer research.
[25] D. Ransohoff,et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. , 1983, Human pathology.
[26] P. Nowell. The clonal evolution of tumor cell populations. , 1976, Science.
[27] J. Kirsner,et al. Carcinoma of the colon in ulcerative colitis , 1964, Cancer.
[28] J. Kirsner,et al. Carcinoma and ulcerative colitis, a clinical-pathologic study. II. Statistical analysis. , 1958, Gastroenterology.
[29] J. Kirsner,et al. Carcinoma and ulcerative colitis, a clinical-pathologic study. I. Cancer deaths. , 1958, Gastroenterology.